Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28867630 | 0.89 | CA1 (0.37) | CA1CA2SRCPIM1PIM2 | |
| SCHEMBL1303570 | 0.82 | IKBKB (0.31) | — | |
| SCHEMBL1303522 | 0.78 | ALDH1A1 (0.34) | ALDH1A1CTNNB1 | |
| SCHEMBL6687092 | 0.78 | IKBKB (0.33) | — | |
| SCHEMBL1303224 | 0.78 | — | — | |
| SCHEMBL1303608 | 0.77 | HSP90AB1 (0.32) | — | |
| SCHEMBL31681546 | 0.76 | LPL (0.33) | — | |
| SCHEMBL26133582 | 0.76 | NPC1 (0.45) | CA1CA2NPC1RAB9AALDH1A1 | |
| SCHEMBL6687711 | 0.75 | — | — | |
| SCHEMBL2557949 | 0.75 | FDPS (0.41) | ALDH1A1HPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982668-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | Pharmacyclics LLC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9162986-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS LLC (US) | 2015-10-20 | — | — | US | disclosed |
| EP-1569912-B1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS INC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS LLC | 2014-12-25 | — | — | US | disclosed |
| US-8778625-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130157298-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYCLICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8299110-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors | PHARMACYCLICS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110269806-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYLICS, INC. A DELAWARE CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
| US-7479502-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | PHARMACYCLICS LLC | 2006-09-14 | — | — | US | disclosed |
| EP-1569912-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050637-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | F7, F9, F5 | CA1 473/4885CA2 945/4885SRC 214/4885 |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | F13B, HABP2, F7 | CA1 2225/4885CA2 2419/4885SRC 1382/4885 |
| US-20110269806-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | F13B, HABP2, F7 | CA1 2225/4885CA2 2419/4885SRC 1382/4885 |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | F13B, HABP2, F7 | CA1 2225/4885CA2 2419/4885SRC 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.